Levels of sirolimus in Saliva vs. Blood - the rationale of topical oral use for oral malignancy

Zakhar Nudelman, Naama Keshet, Michal Dranitzki Elhalal, Michael Friedman, Rakefet Czerninski

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: Sirolimus is a potent blocker of mammalian target of Rapamycin (MTOR), with anti proliferative activity. Its potential for the management of oral cancer has been suggested. Our aim was to establish an analytical method for determining sirolimus levels in human saliva and to calculate the blood vs. saliva ratio in individuals using sirolimus chronically in order to evaluate the total oral tissue exposure. Patients and Methods: Chemiluminescent microparticle immunoassay technology (CMIA) was used to determine the blood and saliva levels of sirolimus in four transplant patients chronically-treated with sirolimus. Results: An analytical method for determining sirolimus levels in human saliva was established. We demonstrated that saliva levels were on average six times lower than blood levels. Conclusion: The specific sensitive analytical method showed that the saliva levels of sirolimus are significantly lower than blood levels, thus reinforcing the rationale for the use of topical oral sirolimus to enhance availability, efficacy and safety for treating oral malignancies.

    Original languageEnglish
    Pages (from-to)661-664
    Number of pages4
    JournalAnticancer Research
    Volume33
    Issue number2
    StatePublished - Feb 2013

    Keywords

    • Oral cancer
    • Oral topical delivery
    • Saliva
    • Sirolimus

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Levels of sirolimus in Saliva vs. Blood - the rationale of topical oral use for oral malignancy'. Together they form a unique fingerprint.

    Cite this